EXCLUSIVE: Nano-Cap Nexalin's Drug-Free Alternative For Alzheimer's Shows Improved Memory, Cognitive Function In Small Study

Benzinga10-17

On Thursday, Nexalin Technology, Inc (NASDAQ:NXL) (NASDAQ:NXLIW) announced results from a clinical trial of its Deep Intracranial Frequency Stimulation (DIFS) technology for mild Alzheimer’s disease. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2476400001?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/CLedPQkBWREdmY2VqYbFVg--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/626de2cf2ea068f1a745c32c264c44b8","is_english":true,"pubTime":"2024-10-17 20:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2476400001","market":"us","top_or_hot":-1,"title":"EXCLUSIVE: Nano-Cap Nexalin's Drug-Free Alternative For Alzheimer's Shows Improved Memory, Cognitive Function In Small Study","media":"Benzinga","content":"<div>\n<p>On Thursday, Nexalin Technology, Inc (NASDAQ:NXL) (NASDAQ:NXLIW) announced results from a clinical trial of its Deep Intracranial Frequency Stimulation (DIFS) technology for mild Alzheimer’s disease.\n...</p>\n\n<a href=\"https://finance.yahoo.com/news/exclusive-nano-cap-nexalins-drug-120041443.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EXCLUSIVE: Nano-Cap Nexalin's Drug-Free Alternative For Alzheimer's Shows Improved Memory, Cognitive Function In Small Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEXCLUSIVE: Nano-Cap Nexalin's Drug-Free Alternative For Alzheimer's Shows Improved Memory, Cognitive Function In Small Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-17 20:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/exclusive-nano-cap-nexalins-drug-120041443.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On Thursday, Nexalin Technology, Inc (NASDAQ:NXL) (NASDAQ:NXLIW) announced results from a clinical trial of its Deep Intracranial Frequency Stimulation (DIFS) technology for mild Alzheimer’s disease.\n...</p>\n\n<a href=\"https://finance.yahoo.com/news/exclusive-nano-cap-nexalins-drug-120041443.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://finance.yahoo.com/news/exclusive-nano-cap-nexalins-drug-120041443.html","article_id":"2476400001","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/CLedPQkBWREdmY2VqYbFVg--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/626de2cf2ea068f1a745c32c264c44b8"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2476400001","pubTimestamp":1729166441,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"On Thursday, Nexalin Technology, Inc   announced results from a clinical trial of its Deep Intracranial Frequency Stimulation  technology for mild Alzheimer’s disease.The full results have been published in Alzheimer’s Research & Therapy.The study demonstrated improvements in memory and cognitive function for patients with mild Alzheimer’s disease using DIFS technology.Also Read: Nano-Cap Nexalin Technology Secures US Patent For Stimulation Device For Alzheimer’s And Dementia Treatment.The 46-patient study showed that those in the DIFS group  saw notable improvements in key cognitive markers, including significant gains in Mini-Mental State Examination  scores  and Montreal Cognitive Assessment  scores .Compared to the sham group, the DIFS group exhibited a statistically significant improvement in memory, as measured by the Alzheimer’s Disease Assessment Scale-Cognitive Subscale .This article EXCLUSIVE: Nano-Cap Nexalin's Drug-Free Alternative For Alzheimer's Shows Improved Memory, Cog","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","NXLIW":"NEXALIN TECHNOLOGY INC C/WTS (TO PUR COM)","NXL":"Nexalin Technology, Inc."},"translate_title":"独家：Nano-Cap Nexalin治疗阿尔茨海默病的无药物替代品在小型研究中显示出改善记忆力和认知功能","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NXLIW":1,"NXL":0.9},"content_text":"On Thursday, Nexalin Technology, Inc (NASDAQ:NXL) (NASDAQ:NXLIW) announced results from a clinical trial of its Deep Intracranial Frequency Stimulation (DIFS) technology for mild Alzheimer’s disease.\nThe full results have been published in Alzheimer’s Research & Therapy.\nThe study demonstrated improvements in memory and cognitive function for patients with mild Alzheimer’s disease using DIFS technology.\nAlso Read: Nano-Cap Nexalin Technology Secures US Patent For Stimulation Device For Alzheimer’s And Dementia Treatment.\nThe 46-patient study showed that those in the DIFS group (23 patients) saw notable improvements in key cognitive markers, including significant gains in Mini-Mental State Examination (MMSE) scores (p = 0.041) and Montreal Cognitive Assessment (MoCA) scores (p = 0.025).\nCompared to the sham group, the DIFS group exhibited a statistically significant improvement in memory, as measured by the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog).\nThe intervention also increased local neural activity in the hippocampus, a crucial brain area for memory processing.\nNexalin’s DIFS treatment also showed increased blood flow to the hippocampal regions critical to memory function. The treatment was well-tolerated, with minor side effects such as mild tingling during stimulation sessions, resolved quickly.\nMark White, CEO of Nexalin Technology, further noted, “Our DIFS technology shows great promise as a drug-free alternative or in combination with existing treatments by working directly on the brain’s electrical activity to modulate cognition. The increase in both neural activity and blood flow in critical areas like the hippocampus indicates that this therapy could potentially slow disease progression.”\nPrice Action: At last check Thursday, NXL stock was up 4.76% at $1.10 during the premarket session.\nAlso Read:\n\nSyfovre’s Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch.\n\nUNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.\nGet the latest stock analysis from Benzinga?\n\nThis article EXCLUSIVE: Nano-Cap Nexalin's Drug-Free Alternative For Alzheimer's Shows Improved Memory, Cognitive Function In Small Study originally appeared on Benzinga.com\n© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2476400001"}